El País in English1d
Winnie Byanyima, from UNAIDS: ‘Lenacapavir is more effective than condoms or PrEP in prevention’
The executive director of the organization says gender inequality is one of the most important drivers of new infections, ...
Gilead, MRK Report Data From Investigational Combination Study for HIV
GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.
pharmaphorum3d
Gilead, MSD say HIV combo could be weekly, oral HIV drug
Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...
Business Wire4d
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapav…
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...